These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 17479360)

  • 1. Carimune NF Liquid is a safe and effective immunoglobulin replacement therapy in patients with primary immunodeficiency diseases.
    Berger M; Cunningham-Rundles C; Bonilla FA; Melamed I; Bichler J; Zenker O; Ballow M
    J Clin Immunol; 2007 Sep; 27(5):503-9. PubMed ID: 17479360
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Multicentre Study on the Efficacy, Safety and Pharmacokinetics of IqYmune®, a Highly Purified 10% Liquid Intravenous Immunoglobulin, in Patients with Primary Immune Deficiency.
    Krivan G; Chernyshova L; Kostyuchenko L; Lange A; Nyul Z; Derfalvi B; Musial J; Bellon A; Kappler M; Sadoun A; Bernatowska E
    J Clin Immunol; 2017 Aug; 37(6):539-547. PubMed ID: 28711959
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of Hizentra(®) in patients with primary immunodeficiency after a dose-equivalent switch from intravenous or subcutaneous replacement therapy.
    Jolles S; Bernatowska E; de Gracia J; Borte M; Cristea V; Peter HH; Belohradsky BH; Wahn V; Neufang-Hüber J; Zenker O; Grimbacher B
    Clin Immunol; 2011 Oct; 141(1):90-102. PubMed ID: 21705277
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Personal experience with replacement therapy with intravenous gamma globulin].
    Litzman J; Lokaj J; Stikarovská D; Mayer J; Thon V; Eibl MM
    Vnitr Lek; 1995 Nov; 41(11):759-63. PubMed ID: 8553594
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravenous immunoglobulin 10% in children with primary immunodeficiency diseases.
    Ochs HD; Melamed I; Borte M; Moy JN; Pyringer B; D Kobayashi AL; Knutsen AP; Smits W; Pituch-Noworolska A; Kobayashi RH
    Immunotherapy; 2018 Oct; 10(14):1193-1202. PubMed ID: 30088423
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adverse reactions of prophylactic intravenous immunoglobulin infusions in Iranian patients with primary immunodeficiency.
    Aghamohammadi A; Farhoudi A; Nikzad M; Moin M; Pourpak Z; Rezaei N; Gharagozlou M; Movahedi M; Atarod L; Afshar AA; Bazargan N; Hosseinpoor AR
    Ann Allergy Asthma Immunol; 2004 Jan; 92(1):60-4. PubMed ID: 14756466
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prospective open-label study of pharmacokinetics, efficacy and safety of a new 10% liquid intravenous immunoglobulin in patients with hypo- or agammaglobulinemia.
    Björkander J; Nikoskelainen J; Leibl H; Lanbeck P; Wallvik J; Lumio JT; Braconier JH; Pavlova BG; Birthistle K; Engl W; Walter S; Ehrlich HJ
    Vox Sang; 2006 May; 90(4):286-93. PubMed ID: 16635071
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of Gammaplex(®) 5% in children and adolescents with primary immunodeficiency diseases.
    Melamed IR; Gupta S; Stratford Bobbitt M; Hyland N; Moy JN
    Clin Exp Immunol; 2016 May; 184(2):228-36. PubMed ID: 26696596
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of a new 10% intravenous immunoglobulin in patients receiving replacement therapy for primary immunodeficiency.
    Wasserman RL; Church JA; Peter HH; Sleasman JW; Melamed I; Stein MR; Bichler J;
    Eur J Pharm Sci; 2009 Jun; 37(3-4):272-8. PubMed ID: 19491015
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of intravenous immunoglobulin on clinical and immunological findings of patients with humoral immunodeficiency diseases.
    Ersoy F; Tezcan I; Sanal O
    Turk J Pediatr; 1992; 34(4):203-9. PubMed ID: 1306339
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tolerability of a new 10% liquid immunoglobulin for intravenous use, Privigen, at different infusion rates.
    Sleasman JW; Duff CM; Dunaway T; Rojavin MA; Stein MR
    J Clin Immunol; 2010 May; 30(3):442-8. PubMed ID: 20217199
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune globulin (human) 10 % liquid: a review of its use in primary immunodeficiency disorders.
    McCormack PL
    BioDrugs; 2013 Aug; 27(4):393-400. PubMed ID: 23703447
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immediate infusion-related adverse reactions to intravenous immunoglobulin in a prospective cohort of 1765 infusions.
    Bichuetti-Silva DC; Furlan FP; Nobre FA; Pereira CT; Gonçalves TR; Gouveia-Pereira M; Rota R; Tavares L; Mazzucchelli JT; Costa-Carvalho BT
    Int Immunopharmacol; 2014 Dec; 23(2):442-6. PubMed ID: 25257732
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Subcutaneous immunoglobulin replacement therapy for primary antibody deficiency: advancements into the 21st century.
    Moore ML; Quinn JM
    Ann Allergy Asthma Immunol; 2008 Aug; 101(2):114-21; quiz 122-3, 178. PubMed ID: 18727465
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety, efficacy and pharmacokinetics of a new 10% liquid intravenous immunoglobulin (IVIG) in patients with primary immunodeficiency.
    Wasserman RL; Church JA; Stein M; Moy J; White M; Strausbaugh S; Schroeder H; Ballow M; Harris J; Melamed I; Elkayam D; Lumry W; Suez D; Rehman SM
    J Clin Immunol; 2012 Aug; 32(4):663-9. PubMed ID: 22392046
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adverse reactions in a large cohort of patients with inborn errors of immunity receiving intravenous immunoglobulin.
    Esmaeilzadeh H; Askarisarvestani A; Hosseini N; Samimi S; Shafiei A; Mahdaviani SA; Eslami N; Chavoshzadeh Z; Fallahi M; Khakbazanfard N; Shabestari MS; Aleyasin S; Nabavizadeh SH; Cheraghi T; Kalantari A; Ahmadiafshar A; Safari M; Eslamian MH; Molatefi R; Shirkani A; Heidarzadeh Arani M; Tavakol M; Bemanian MH; Arshi S; Nabavi M; Shokri S; Shahhosseini B; Mortazavi N; Nakhaei P; Nazari F; Fallahpour M; Ahanchian H; Moazzen N; Khoshkhui M; Motlagh AV; Aghamohammadi A; Abolhassani H; Yazdani R; Rezaei N
    Clin Immunol; 2021 Sep; 230():108826. PubMed ID: 34418548
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of subcutaneous IgPro20 in patients with primary immunodeficiency.
    Wasserman RL; Melamed I; Nelson RP; Knutsen AP; Fasano MB; Stein MR; Rojavin MA; Church JA
    Clin Pharmacokinet; 2011 Jun; 50(6):405-14. PubMed ID: 21553933
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy, safety, and pharmacokinetics of a 10% liquid immune globulin preparation (GAMMAGARD LIQUID, 10%) administered subcutaneously in subjects with primary immunodeficiency disease.
    Wasserman RL; Melamed I; Kobrynski L; Strausbaugh SD; Stein MR; Sharkhawy M; Engl W; Leibl H; Sobolevsky L; Gelmont D; Schiff RI; Grossman WJ
    J Clin Immunol; 2011 Jun; 31(3):323-31. PubMed ID: 21424824
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of Privigen, a novel 10% liquid immunoglobulin preparation for intravenous use, in patients with primary immunodeficiencies.
    Stein MR; Nelson RP; Church JA; Wasserman RL; Borte M; Vermylen C; Bichler J;
    J Clin Immunol; 2009 Jan; 29(1):137-44. PubMed ID: 18814020
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics and safety of Intragam 10 NF, the next generation 10% liquid intravenous immunoglobulin, in patients with primary antibody deficiencies.
    Bleasel K; Heddle R; Hissaria P; Stirling R; Stone C; Maher D
    Intern Med J; 2012 Mar; 42(3):252-9. PubMed ID: 22212346
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.